EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gilead Sciences's enterprise value is $101,220 Mil.
Gilead Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $10,496 Mil. Therefore, Gilead Sciences's EV-to-EBITDA for today is 9.64.
The historical rank and industry rank for Gilead Sciences's EV-to-EBITDA or its related term are showing as below:
GILD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.3 Med: 10.55 Max: 57.02
Current: 9.64
During the past 13 years, the highest EV-to-EBITDA of Gilead Sciences was 57.02. The lowest was 5.30. And the median was 10.55.
GILD's EV-to-EBITDA is ranked better than 66.76% of 707
companies
in the Drug Manufacturers industry
Industry Median: 13.81
vs GILD: 9.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Gilead Sciences's stock price is $67.03.
Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $4.500. Therefore, Gilead Sciences's PE Ratio for today is 14.90.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Gilead Sciences EV-to-EBITDA Historical Data
The historical data trend for Gilead Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Gilead Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences EV-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's EV-to-EBITDA falls into.
Gilead Sciences EV-to-EBITDA Calculation
Gilead Sciences's EV-to-EBITDA for today is calculated as:
Gilead Sciences's current Enterprise Value is $101,220 Mil.
Gilead Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,496 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Gilead Sciences's PE Ratio for today is calculated as:
Gilead Sciences's share price for today is $67.03.
Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Gilead Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences (Gilead Sciences) Business Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GILD has been successfully added to your 